Exocrine Pancreatic Insufficiency: all 129 studies
Page 2 of 2. Open to participants first (26), then studies with results posted, then the rest; newest registration first within each.
- Pancreatic Insufficiency Secondary to Tobacco ExposureCompletedNCT01988350
- Creon Use in Coeliac Patients With Low Faecal Pancreatic ElastaseTerminatedNCT01865695Phase 4
- Pancreatic Exocrine Insufficiency and Pancreatic Enzyme Supplementation in Critically Ill Adult PatientsCompletedNCT01753024
- Efficacy and Tolerability of NM-BL in Patients With Exocrine Pancreatic Insufficiency Due to Cystic FibrosisCompletedNCT01710644Phase 1/2
- Safety and Efficacy Study of 2 Pancreatic Enzymes for Treatment of Exocrine Pancreatic Insufficiency in Cystic Fibrosis.CompletedNCT01641393Phase 3
- Enzyme Suppletion in Exocrine Pancreatic DysfunctionCompletedNCT01430234Phase 4
- Baby Observational and Nutritional StudyCompletedNCT01424696
- A Study of EUR-1066 in Subjects With Chronic Pancreatitis, Exocrine Pancreatic Insufficiency and Chronic Abdominal PainTerminatedNCT01159119Phase 1
- Prediction by Ultrasound of the Risk of Hepatic Cirrhosis in Cystic FibrosisCompletedNCT01144507
- Comparison of Secretin-enhanced Magnetic Resonance Cholangiopancreatography (S-MRCP) to Endoscopic Pancreatic Function Test (ePFT) in Diagnosing Pancreatic Exocrine InsufficiencyWithdrawnNCT01094600Not applicable
- Clinical Non-Inferiority of Pancreatic Enzymes (Norzyme ® - Bergamo) Compared To Creon ® (Solvay Pharmaceutical) in Patients With Exocrine Pancreatic InsufficiencyStatus unknownNCT01012908Phase 2/3
- Bioavailability of Pancreatic Enzymes in the Human Upper Intestine (Duodenum and Jejunum)TerminatedNCT00749099Not applicable
- Intraduodenal Aspiration Study to Assess the Bioavailability of Oral Pancrecarb® Compared to Placebo ControlTerminatedNCT00744250Phase 4
- Creon 40,000 for Treatment of PEI (Pancreatic Exocrine Insufficiency) Due to Chronic PancreatitisCompletedNCT00705978Phase 3
- A Study of the Enzyme Activity and Safety of Pancrelipase in Patients With Severe Exocrine Pancreatic Insufficiency (EPI)CompletedNCT00676702Phase 1
- Open Label Safety Study of DCI-1020 in Pediatric Cystic Fibrosis (CF) PatientsWithdrawnNCT00663975Not applicable
- Dose-ranging Study to Evaluate Efficacy of SLV339 in Pancreatic Exocrine Insufficiency Due to Chronic PancreatitisTerminatedNCT00630279Phase 2
- Malabsorption Blood Test:Toward a Novel Approach to Quantify SteatorrheaCompletedNCT00572975Phase 4
- An Open-Label Study to Evaluate the Intraduodenal Delivery of Enzymes From Administration of VIOKASE16 in Exocrine Pancreatic Insufficiency (EPI)CompletedNCT00559052Phase 2
- Creon After Pancreatic SurgeryCompletedNCT00535756Phase 4
- Phase III ALTU-135 CP Safety TrialTerminatedNCT00500084Phase 3
- Open-Label Phase III Long-Term Safety Trial of LiprotamaseCompletedNCT00449904Phase 3
- Liprotamase Efficacy Trial in Patients With Cystic Fibrosis-Related Exocrine Pancreatic InsufficiencyCompletedNCT00449878Phase 3
- Evaluation of the Safety and Efficacy of Pancrecarb® MS-16 in Cystic FibrosisCompletedNCT00432861Phase 3
- Study of LYM-X-SORB™ to Improve Fatty Acid and Choline Status in Children With CF and PICompletedNCT00406536Phase 2
- A Open-label Study to Assess the Safety of Oral Long-term Use of SA-001 in Pancreatic Exocrine InsufficiencyCompletedNCT00401076Phase 3
- A Study of SA-001 to Treat Pancreatic Exocrine InsufficiencyCompletedNCT00400842Phase 3
- Oral TheraCLEC™ - Total in Cystic Fibrosis Subjects With Exocrine Pancreatic InsufficiencyCompletedNCT00095732Phase 2
- Diagnosis and Treatment of Patients With Cystic FibrosisTerminatedNCT00001223